Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly
Nov 18
Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedNov 21, 2024
DataAggregated Company Financials
Companies73
- 7D-3.9%
- 3M20.9%
- 1Y-16.5%
- YTD-15.8%
Over the last 7 days, the Biotech industry has dropped 6.3%, and Chongqing Zhifei Biological Products contributed the most with a 7.3% decline. Meanwhile, HOB Biotech GroupLtd actually outperformed within the industry, gaining 11% in the last week. The industry has fallen 19% in the last year. Earnings are forecast to grow by 44% annually.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 21 Nov 2024 | CN¥933.1b | CN¥141.7b | CN¥11.2b | 37.5x | 83.3x | 6.6x |
| Sat, 19 Oct 2024 | CN¥908.3b | CN¥154.1b | CN¥14.5b | 38.3x | 62.9x | 5.9x |
| Mon, 16 Sep 2024 | CN¥737.3b | CN¥154.1b | CN¥14.5b | 30.8x | 50.8x | 4.8x |
| Wed, 14 Aug 2024 | CN¥827.9b | CN¥161.2b | CN¥17.3b | 31.4x | 47.9x | 5.1x |
| Fri, 12 Jul 2024 | CN¥829.6b | CN¥161.1b | CN¥17.3b | 32.6x | 48x | 5.1x |
| Sun, 09 Jun 2024 | CN¥877.3b | CN¥161.1b | CN¥17.3b | 31.5x | 50.7x | 5.4x |
| Tue, 07 May 2024 | CN¥985.1b | CN¥161.2b | CN¥17.3b | 36.8x | 57.1x | 6.1x |
| Thu, 04 Apr 2024 | CN¥965.0b | CN¥161.0b | CN¥20.1b | 39.9x | 47.9x | 6x |
| Sat, 02 Mar 2024 | CN¥1.0t | CN¥165.5b | CN¥22.0b | 36.4x | 45.8x | 6.1x |
| Mon, 29 Jan 2024 | CN¥964.3b | CN¥167.9b | CN¥21.4b | 35.1x | 45x | 5.7x |
| Wed, 27 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.4x | 50.8x | 6.5x |
| Fri, 24 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.8x | 52.6x | 6.7x |
| Sun, 22 Oct 2023 | CN¥1.0t | CN¥171.1b | CN¥25.3b | 39.1x | 40.3x | 6x |
| Tue, 19 Sep 2023 | CN¥1.0t | CN¥170.9b | CN¥25.2b | 39.3x | 41.5x | 6.1x |
| Thu, 17 Aug 2023 | CN¥1.0t | CN¥173.8b | CN¥28.1b | 38.4x | 37x | 6x |
| Sat, 15 Jul 2023 | CN¥1.1t | CN¥177.2b | CN¥29.9b | 39.7x | 35.8x | 6x |
| Mon, 12 Jun 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 39x | 36.9x | 6.1x |
| Wed, 10 May 2023 | CN¥1.2t | CN¥177.6b | CN¥29.5b | 42.1x | 39.1x | 6.5x |
| Fri, 07 Apr 2023 | CN¥1.2t | CN¥186.0b | CN¥36.6b | 40.5x | 34x | 6.7x |
| Sun, 05 Mar 2023 | CN¥1.3t | CN¥178.9b | CN¥36.0b | 42.9x | 35.5x | 7.1x |
| Tue, 31 Jan 2023 | CN¥1.3t | CN¥179.6b | CN¥38.0b | 43.3x | 34.8x | 7.4x |
| Thu, 29 Dec 2022 | CN¥1.2t | CN¥175.6b | CN¥37.9b | 38.1x | 31.5x | 6.8x |
| Sat, 26 Nov 2022 | CN¥1.2t | CN¥175.5b | CN¥37.9b | 39x | 32.5x | 7x |
| Mon, 24 Oct 2022 | CN¥1.2t | CN¥175.6b | CN¥41.1b | 34.7x | 29.1x | 6.8x |
| Wed, 21 Sep 2022 | CN¥1.1t | CN¥174.0b | CN¥40.1b | 30.5x | 28.4x | 6.6x |
| Fri, 19 Aug 2022 | CN¥1.2t | CN¥172.5b | CN¥43.6b | 35.7x | 28.4x | 7.2x |
| Sun, 17 Jul 2022 | CN¥1.3t | CN¥168.3b | CN¥42.5b | 36.1x | 30.1x | 7.6x |
| Tue, 14 Jun 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 36.3x | 28.7x | 7.2x |
| Thu, 12 May 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 35.8x | 29.2x | 7.4x |
| Sat, 09 Apr 2022 | CN¥1.4t | CN¥153.1b | CN¥40.8b | 41.1x | 34.4x | 9.2x |
| Mon, 07 Mar 2022 | CN¥1.4t | CN¥152.0b | CN¥40.7b | 48x | 35.3x | 9.4x |
| Wed, 02 Feb 2022 | CN¥1.4t | CN¥143.8b | CN¥38.7b | 43.1x | 35x | 9.4x |
| Fri, 31 Dec 2021 | CN¥1.5t | CN¥141.8b | CN¥38.5b | 51x | 39.9x | 10.8x |
| Sun, 28 Nov 2021 | CN¥1.6t | CN¥145.1b | CN¥40.2b | 48.2x | 40.9x | 11.3x |
Price to Earnings Ratio
40.9x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 82.0x which is higher than its 3-year average PE of 40.7x.
- The industry is trading close to its 3-year average PS ratio of 6.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 35% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -3.39% | |
| Healthcare | -2.41% | |
| Biotech | -3.91% | |
| Biotech | -3.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688656 HOB Biotech GroupLtd | CN¥145.00 | 22.9% +CN¥1.7b | 257.8% | PE256x | |
| 002252 Shanghai RAAS Blood Products | CN¥7.71 | 2.3% +CN¥1.1b | 3.8% | PE27.8x | |
| 688192 Dizal (Jiangsu) Pharmaceutical | CN¥47.91 | 5.7% +CN¥1.1b | 9.8% | PS51.1x | |
| 300294 China Resources Boya Bio-pharmaceutical GroupLtd | CN¥32.63 | 4.2% +CN¥670.7m | 1.0% | PE88.4x | |
| 688298 Zhejiang Orient Gene Biotech | CN¥36.45 | 9.4% +CN¥602.8m | -15.0% | PS8.5x |